PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
Public ClinicalTrials.gov record NCT02374060. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the relative efficacy of three commonly utilized regional corticosteroids for the regional treatment of uveitic macular edema: periocular triamcinolone acetonide; intravitreal triamcinolone acetonide; intravitreal dexamethasone implant. The primary efficacy measure will be percent change in central subfield thickness as measured by OCT at 8 weeks. Participants will continue in the study for 24 weeks in order to evaluate relative effects of the 3 treatment strategies on the duration of treatment effects, requirement for additional injections, and adverse effects. Note: The planned sample size for the POINT Trial was 267 subjects. On 17 July 2017, with 192 subjects enrolled, the Data and Safety Monitoring Committee (DSMC) reviewed the planned interim analysis and recommended that the goals of the trial could be accomplished by completing follow-up of enrolled subjects without the recruitment of additional subjects. Per the DSMC recommendations, recruitment was suspended and follow-up of enrolled subjects was completed according to the protocol.
Study identification
- NCT ID
- NCT02374060
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 192 participants
Conditions and interventions
Conditions
Interventions
- Periocular triamcinolone 40 mg Drug
- Intravitreal triamcinolone 4 mg Drug
- Dexamethasone intravitreal implant Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 16, 2015 (Actual)
- Primary completion
- Aug 30, 2017 (Actual)
- Completion
- Jan 4, 2018 (Actual)
- Last update posted
- Dec 4, 2018
2015 – 2018
United States locations
- U.S. sites
- 23
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Jules Stein Eye Institute, UCLA | Los Angeles | California | 90095 | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
| Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine | Miami | Florida | 33136 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| National Eye Institute, NIH | Bethesda | Maryland | 20892 | — |
| Massachusetts Eye and Ear Infirmary | Boston | Massachusetts | 02114 | — |
| Ophthalmic Consultants of Boston | Boston | Massachusetts | 02114 | — |
| Kellogg Eye Center, University of Michigan | Ann Arbor | Michigan | 48105 | — |
| MAYO Clinic | Rochester | Minnesota | 55905 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| New York Eye and Ear Infirmary | New York | New York | 10016 | — |
| Duke Eye Center, Duke University | Durham | North Carolina | 27710 | — |
| Scheie Eye Institute, University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Wills Eye Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Unniversity of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Vitreoretinal Consultants | Houston | Texas | 77030 | — |
| John A. Moran Eye Center, University of Utah | Salt Lake City | Utah | 84132 | — |
| University of Washington | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02374060, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 4, 2018 · Synced Nov 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02374060 live on ClinicalTrials.gov.